WHO briefing
on *Malaria Treatment Guidelines*
and artemisinin monotherapies

Geneva, 19 April 2006
© World Health Organization 2006

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The named authors alone are responsible for the views expressed in this publication.
EXECUTIVE SUMMARY

WHO recommends the use of artemisinin-based combination therapies (ACTs) in order to ensure high cure rates of *Plasmodium falciparum* malaria and to reduce the spread of drug resistance. The majority of falciparum endemic countries have adopted ACTs as first-line treatment and deployment of ACTs in the public sector has increased exponentially during the past 3 years. In the private sectors, however, the artemisinin derivatives are mainly marketed as monotherapies, and their consumption, if unabated, will promote development and spread of resistance and compromise the effectiveness of ACTs. In order to stimulate the pharmaceutical sector to invest on WHO recommended products and to move away from the marketing of oral artemisinin derivatives, 41 manufacturers active in this sector were invited to a meeting in Geneva.

Twenty-six pharmaceutical companies involved in production and marketing of artemisinin monotherapies for oral treatment of uncomplicated falciparum malaria attended the “WHO Briefing on Malaria Treatment Guidelines and Artemisinin Monotherapies”, held on 19 April 2006 in Executive Board Room, WHO Geneva. With the exception of Sanofi-Aventis, all invited companies were generic manufacturers from Africa (Cameroon, Ghana and United Republic of Tanzania), Asia (China, Malaysia, India and Viet Nam) and Europe (Belgium, Denmark, Germany and Switzerland). The remaining 15 invited companies did not attend for various reasons.

The WHO position was presented and openly discussed with the manufacturers, with specific reference to: i) active promotion of ACTs as the best standard of care for malaria treatment, with a rapidly expanding market size; ii) ongoing efforts to ensure long-term effectiveness of ACTs, reducing deployment of artemisinin monotherapies especially in the private sector to prevent the development of resistance; iii) promoting ACTs of high quality, efficacy and safety and the intention to collaborate with pharmaceutical companies to ensure that they meet quality standards; iv) promoting competition between high quality multi-source products as a sustainable mechanism to ensure low pricing and affordability.

A total of 15 companies declared their willingness to support the WHO position and will stop marketing artemisinin monotherapies over a short period of time. These companies will also increase production and marketing of ACTs in both public and private sector markets. They include: CIPLA, Guilin, IPCA, MEPHA and Sanofi-Aventis, the main producers of ACT in compliance with Good Manufacturing Practices, and currently the sources of ACT procurement for both WHO and UNICEF. Two additional companies expressed their willingness to collaborate with WHO in this endeavour, but the remaining did not disclose their marketing plans for the future.

Most companies requested technical support from WHO to meet the standards of the WHO prequalification programme. In addition, companies demanded clear communication to national drug regulatory authorities of malaria endemic countries to withdraw the marketing authorization for all oral artemisinin monotherapies. This will ensure compliance by all manufacturers and avoid that some companies exploit market opportunities created by the withdrawal of products by manufacturers complying with WHO recommendations.
WHO will work with international funding agencies, multilateral and bilateral agencies, international suppliers to discontinue funding and procurement of oral artemisinin monotherapies and to exclusively procure WHO recommended antimalarial medicines. Multiple fora at international, regional and national levels will be used over the next months to communicate WHO recommendations to National Drug Regulatory Authorities of malaria endemic countries. WHO will work with health professionals to promote rational drug use and abandon the use of oral artemisinin monotherapies.
1. Introduction

Since April 2001, WHO has recommended the use of artemisinin-based combination therapies (ACTs) in countries where *Plasmodium falciparum* malaria is resistant to chloroquine, sulfadoxine-pyrimethamine and amodiaquine. ACTs ensure the highest cure rates and have the potential to reduce the spread of drug resistance. At present, 60 countries have adopted ACTs as recommended by WHO, and 33 are deploying ACTs in the general health services. With increased mobilization of international funds, mainly from the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM), the procurement of ACTs for the public health sector has increased exponentially during the past three years, with more than 30 million ACT treatment courses procured and delivered in 2005. However, in the private sector markets of endemic countries, artemisinin derivatives are used more widely, mainly as monotherapies at lower prices compared to ACTs. Only 11 countries with falciparum-resistant malaria do not currently allow marketing of artemisinin monotherapies (Afghanistan, Brazil, Eritrea, Iran, Mexico, Malaysia, Philippines, Saudi Arabia, Sudan, South Africa and Thailand).

The increasing consumption of artemisinin monotherapies in the private sector, if unabated, will promote resistance to artemisinins and compromise the effectiveness of ACTs. This has happened with the large-scale deployment of all other antimalarial medicines as monotherapies, and for the artemisinin derivatives in particular, the risk is confirmed by the progressive reduction of *in vitro* susceptibility to artemisinin of *P. falciparum* in China and Viet Nam, countries where artemisinins were deployed as monotherapies for many years. If falciparum malaria develops resistance to the artemisinin derivatives, there will be no alternative effective compounds to treat malaria over the next ten years.

2. Background and objectives of the meeting

In January 2006, on the occasion of the release of the *WHO Guidelines for the Treatment of Malaria*, WHO issued a press release urging 17 known companies to stop marketing artemisinin monotherapies, and to re-direct their production efforts towards artemisinin-based combination therapies. The press release received major attention in the international media (newspapers, radio and television) and in the national press in endemic countries. Before the press release was issued, all concerned companies were invited to a technical briefing in Washington, but only two were able to attend. In order to share more information with 41 companies active in this sector, a second meeting was scheduled in Geneva in April 2006, with the following objectives:

- To present and discuss with manufacturers of oral artemisinin derivatives the evidence of potential risks of development of resistance to artemisinins, the WHO recommended product profile for antimalarial medicines, the quality requirements for UN procurement agencies and the ACT forecast for the public sector based on country plans and availability of international funds.
To receive commitments and realistic implementation plans from manufacturers for re-orienting production and marketing efforts away from oral artesinin monotherapies and towards quality ACTs, in line with the WHO recommendations and regulatory measures from the national drug regulatory authorities of endemic countries.

The topics presented by WHO and list of participants are provided in Annexes I and II.

3. Discussion points

WHO has made clear communications to pharmaceutical companies on the need to re-orient production and marketing towards the recommended ACTs and away from oral monotherapies. In addition to this, it must be made clear to national drug regulatory authorities of malaria endemic countries that artemisinin suppositories and injectable formulations as monotherapy are recommended only for the management of severe malaria and should not be used for the treatment of uncomplicated malaria.

A total of 9 countries (Afghanistan, Brazil, Eritrea, Ethiopia, Iran, Malaysia, Philippines, Saudi Arabia, and South Africa) with resistant P.falciparum malaria, have never registered oral artemisinin monotherapies. Thailand has registered oral artesunate in 1994 with a restriction in distribution regulated by the Ministry of Health, which resulted in very limited use, i.e. as third-line treatment for quinine + tetracycline treatment failures. One country, Sudan, has withdrawn the marketing authorization for these products after it adopted and started implementing the new treatment policy based on ACTs. After the WHO press call in January 2006, national health authorities of Benin, Comoros and Gabon have taken formal steps to withdraw marketing authorizations for artemisinin monotherapies in their respective countries.

WHO/GMP has recommended through its Representatives in malaria endemic countries, that national health authorities of all countries with falciparum malaria to comply with newly published WHO Guidelines for the Treatment of Malaria and withdraw the marketing of oral artemisinin monotherapies for the treatment of uncomplicated falciparum malaria. Recently, countries such as India, Kenya, and eleven others in Southern Africa belonging to the Southern African Development Community (Angola, Botswana, Democratic Republic of Congo, Madagascar, Malawi, Mozambique, Namibia, Swaziland, United Republic of Tanzania, Zambia, Zimbabwe) are considering withdrawing marketing authorization for these products.

Apart from the important role of national drug regulatory authorities, pharmaceutical companies also have a shared responsibility in the health of people who consume their products. Companies can contribute to rational drug use by developing antimalarial medicines with therapeutic indications in compliance with WHO treatment guidelines and by influencing prescription practices, especially in the private sector, through their presence and marketing efforts in the countries. In addition, by producing more ACTs of high efficacy, quality and safety, manufacturers will meet the increasing
demand for these medicines and will contribute, through open competition, to reduce the price for end-users.

New ACTs in fixed-dose combination are under development and will enter the market by late 2006 and 2007, including artesunate-amodiaquine, artesunate-mefloquine, artesunate-pyronaridine, dihydroartemisinin-piperaquine and chlorproguanil-dapsone-artesunate. Several manufacturers are working on the fixed-dose combination of artesunate-amodiaquine, including Sanofi-Aventis in partnership with Drugs for Neglected Disease Initiative (DNDi). It was highly appreciated by all that Sanofi-Aventis will not apply intellectual property rights/patents to this medicine and that it will submit the dossier for review to the UN prequalification programme as an innovator product. Several manufacturers are currently developing generic versions of artemether-lumefantrine, with improved dosage forms and formulations that could reduce the number of tablets/dose. These efforts are likely to contribute to an increase in production of this ACT and could lead to price reductions through market competition. An acceleration of the procedure for prequalification of a generic artemether-lumefantrine was requested by several company representatives at the meeting.

There is a need to provide technical and financial resources to support manufacturers in developing countries to meet the requirements of the prequalification programme. WHO encourages companies to apply to this process and will broker financial support from Development Banks, and technical assistance from Development Agencies to support this process. In the interim period, and until more ACT products are prequalified WHO will inform Member States of products and manufacturers meeting Good Manufacturing Practices (GMP) and meeting standards acceptable for procurement by WHO/UNICEF.

The WHO appeal to reduce the use of oral artemisinin monotherapies has had wide resonance and received support from public health specialists, international initiatives such as the Drugs for Neglected Disease Initiative (DNDi), the Médecins Sans Frontières (MSF) Access Campaign and Medicine for Malaria Venture (MMV), as well as from consumer associations in countries. This public health issue and the response to it by pharmaceutical companies has received wide media attention, and the pressure is on WHO to provide regular updates and reports on the alignment by companies, and the results thereof. The issue will be in the media eye in the months to follow.

4. Position statement of participating pharmaceutical companies

The short statements below represent the position expressed by representatives of the companies participating to the meeting.

**Activa Pharmaceuticals (FCZ)**

- This newly established company is a joint venture of Holley-IPCA and is exclusively committed to the marketing of ACTs, which has given the name to this company.
Ajanta Pharma Limited

- The company decided to stop production and marketing of monotherapies and is investing exclusively in ACT fixed-dose combinations.

Arenco Pharmaceutica

- The company decided in January not to launch its oral paediatric formulation of artemisinin monotherapy following WHO appeal to manufacturers, despite considerable R&D investment in this product. The company is investing in the development of a fixed-dose combination as they do not believe co-blistering to be a good solution in an African setting.

Chongqing Holley Holding Co., Ltd. (representing also Holley-Cotec Pharmaceuticals and Holleypharm France)

- The company is fully committed to ACT as one of the major pharmaceutical products to launch the image of company at international level. The company will progressively stop producing its dihydroartemisinin monotherapy and will invest in marketing of a new fixed-dose combination therapy, dihydroartemisinin+piperazine. This medicine is entering Phase III clinical trials as part of a collaborative project with MMV. In addition, the company is willing to submit its product dossier to the UN prequalification programme, once this ACT is added to the list of medicines to be prequalified.

Cipla Limited

- The company is committed to work with WHO on the progressive reduction of marketing of artemisinin monotherapies, and requested WHO support to increase reliability of forecasting of requirements for public sector use, promote sustained financial mechanisms for ACT procurement and support development of generic artemether-lumefantrine.

Dafra Pharma NV

- The company agrees fully to phase out its oral single tablet artesunate and artemether suspension monotherapies for uncomplicated malaria in favour of introducing ACTs. The company points out that it has already shifted its entire R&D budget to ACTs since the first recommendation of the WHO in this regard in 2001. The company has developed several ACTs, initially in co-blisters and some already in fixed-dose combinations: artesunate+sulfadoxine-pyrimethamine; artemether+lumefantrine; artesunate+amodiaquine; artesunate+sulfamethoxypyrazine-pyrimethamine. All these ACTs are already present in the market or are at the phase of being registered. The company will proceed in its marketing strategy to actively promote ACTs and to help convince local health authorities to withdraw the marketing authorization for all oral artemisinin monotherapies for uncomplicated malaria. According to the company this phasing out can only be successful if all partners involved
(manufacturers, national health authorities & customs services in Africa, hospitals & pharmacies, NGOs, primary health care services and health professionals) work closely together under WHO’s guidance. Control systems to ascertain that all oral monotherapies are eliminated from the registration lists in each country should be set up.

Danpong-Adams Pharmaceutical Industry Ltd.

- The company is investing in amodiaquine+artesunate as co blister product for registration in Ghana and requested technical support to WHO to achieve GMP. The company did not express its position on marketing of artemisinin monotherapies.

Denk Pharma GmbH & Co. KG

- The company decided to stop production and marketing of oral artemisinin monotherapies following WHO press release in January and will now stop marketing its artemether oral suspension. It will invest in the development of a rectal artemether formulation for use as a pre-referral treatment option, and concentrate marketing and sales activities on its combination of artesunate+ sulphamethoxypyrazine-pyrimethamine.

Guilin Pharmaceutical Co., Ltd.

- The company will comply with WHO’s request and has stopped new production of artesunate monotherapies; it expects stocks to be progressively extinguished over the next few months. It will invest its marketing efforts on the artesunate+amodiaquine co blister for which its manufacturing sites have been inspected and certified as GMP compliant by the WHO inspection team.

Hovid Bhd

- The company has registered an artemisinin monotherapy in Malaysia after a long regulatory process, but following the WHO recommendations will proceed to the phasing out of this product. The company requested technical support from WHO on selection and investment of alternative ACTs.

IPCA Laboratories Ltd.

- The company is committed to research and development for fixed dose ACT products, and to invest in sustained release products and paediatric formulations. IPCA is committed to collaborate with WHO and will stop marketing of artemisinin monotherapy once the national drug regulatory authority of India withholds its marketing authorization.
Kakwa Biofarm, Ltd.

- The company has developed amodiaquine+artesunate co-blister, which has been submitted for registration in Cameroon and will be mainly marketed for the domestic use. The company had stopped the manufacture of artesunate monotherapy and is working towards formulating a fixed-dose combination of amodiaquine+artesunate and requested technical support to WHO to comply with GMP.

Kinapharma Ltd.

- The company did not express its position on marketing of artemisinin monotherapies.

Kunming Pharmaceuticals

- KPC will cooperate with WHO for implementing the policy of stopping oral artemisinin monotherapy, on general concerns on risk of development of resistance to artemisinin monotherapy. KPC will stop marketing of artemisinin monotherapy over a certain timeframe taking into consideration the availability of effective antimalarials by the patients. KPC has made progress in the development of a new fixed-dose combination (artemisinin+ naphthoquinone phosphate tablets) and will invest in the development of this new ACT as the company's major product in the future.

Mediplantex National Pharmaceutical Joint Stock Co.

- The company has developed both amodiaquine+artesunate and dihydroartemisinin-piperaquine as co-blisters, which have been submitted for registration in Viet Nam. The company has a major role as supplier of artemisinin raw materials, 70% of which are for export. The company is prepared to halt the production and marketing of oral artemisinin monotherapies according to WHO's recommendation.

Mepha Ltd.

- The company provided clear commitment to stop marketing its oral artesunate monotherapy, and expects that sales for this product will progressively decline over the remaining part of the year. It will focus its production and marketing efforts on its artesunate rectocaps (suppositories) for pre-referral treatment of severe malaria and on artesunate+mefloquine co-blister for treatment of uncomplicated malaria. The company is developing a fixed-dose paediatric formulation of artesunate+mefloquine, and would appreciate WHO support to meet the requirements of the UN prequalification programme.
Phyto-Riker Pharmaceuticals Ltd.

• The company did not express its position on marketing of artemisinin monotherapies.

Sanofi-Aventis

• The company markets artesunate from Guilin Pharmaceutical Co. Ltd., as a stand-alone drug, and within a co-blister presentation of artemesunate and amodiaquine. The company is committed to the development of a fixed-dose combination of artemesunate-amodiaquine and has stopped marketing activities for artemesunate monotherapy. It expects that sales for the latter product will be progressively reduced over the remaining duration of 2006, and will stop distribution with the launch of the new fixed-dose combination. As a result of the revised marketing strategy recent figures showed that artemesunate-amodiaquine already represented 70% of sales as compared to 30% for artemesunate monotherapy, a trend that is expected to further increase over the coming months.

Saokim Pharma

• The company has a major role as supplier of artemisinin raw materials, both for domestic use and for export, and is establishing new facilities for the production of finished pharmaceutical products. The company did not express its position on the marketing of artemisinin monotherapies. Saokim is developing fixed-dose combination of artesunate-amodiaquine and would appreciate technical support from WHO to improve manufacturing process and the preparation of the drug regulatory dossier.

Scanpharm A/S

• The company fully supports WHO's call to ban artemisinin monotherapy and will invest on production and marketing of a co-blister of artesunate+amodiaquine and artesunate rectal capsules.

Shelys Pharmaceuticals Ltd.

• The company has developed an amodiaquine+artesunate as co-blister and needs GMP certification and technical support to conduct bioequivalence studies. The company did not express its position on marketing of artemisinin monotherapies.

Standard Pharma Ltd.

• The company has a major role as supplier of artemisinin raw materials, which are both for domestic and for export markets, and is not involved in the production of pharmaceutical finished products.
Themis Medicare Ltd

- The company is involved in the production of different artemisinin derivatives, including artemether and artemotil for treatment of severe malaria. The company will stop marketing oral artemisinin monotherapies and will continue investing in production and marketing of parenteral artemisinin formulations.

5. **Next steps of WHO Global Malaria Programme**

1. WHO will continue to work with manufacturers of artemisinin derivatives to promote the production and marketing of quality ACTs in line with *WHO Guidelines for Treatment of Malaria*, and to stop the marketing of oral artemisinin monotherapies for the treatment of uncomplicated malaria.

2. WHO will promote technical support to companies manufacturing ACTs to internationally agreed standards of efficacy, safety and quality. Information on companies producing quality products and found acceptable for procurement by WHO/UNICEF will be shared with all WHO Member States, funding agencies and NGOs.

3. WHO will also work with international funding agencies, multilateral and bilateral agencies, and international medicine suppliers to discontinue funding for, and procurement of oral artemisinin monotherapies and to exclusively procure WHO recommended antimalarial medicines.

4. WHO will share information on the progress made with the pharmaceutical manufacturers, using public forums such as the web and media communication to report positively on companies which act responsibly, complying with the WHO recommendations, and will expose companies which place life-saving ACTs at risk of resistance by continued monotherapy malpractice.

5. Multiple fora at international, regional and national levels will be used over the next months to communicate WHO recommendations to National Drug Regulatory Authorities of malaria endemic countries; 48 countries with falciparum-resistant malaria, including 16 high-burden countries in Africa, have yet to respond to the WHO appeal to withdraw oral artemisinin monotherapies from their markets.

6. WHO will work with health professionals to promote rational drug use and abandon the use of artemisinin monotherapies. The *WHO Treatment Guidelines* will be widely publicized and disseminated, through professional associations, teaching institutions and active distribution networks in the private sector, including the pharmaceutical sector. WHO will continue to work with Member States in adopting these recommendations, and adapting the malaria treatment guidelines to local situations.
ANNEX I

WHO briefing sessions

1. The threat of resistance to artemisinin derivatives

WHO has established a Global database on therapeutic efficacy of antimalarials (www.who.int/malaria/resistance.htm), which is regularly updated on the basis of published studies and validated reports from academic/research institutions and malaria control programmes in endemic countries. When used as monotherapy on a large-scale, *P. falciparum* has developed resistance to all antimalarial medicines over a period of time ranging from less than 1 year (sulfadoxine-pyrimethamine and atovaquone), to 1 year (proguanil), to 5 years (mefloquine), to up to 12 years (chloroquine).

The artemisinin derivatives are one of the most promising antimalarial medicines, offering the following pharmacological properties: i) rapid and sustained reduction of the parasite biomass; ii) effective against resistant parasites; iii) rapid resolution of clinical symptoms; iv) reduction of gametocyte carriage; v) broad stage specificity; vii) 7-day treatment in monotherapy. Resistance to artemisinin derivatives has been induced experimentally in rodent malaria; resistance to artemisinin and artemether has been obtained in *P. yoelii* and *P. berghei*, with reversal after drug pressure removal. Stable genetic resistance to artemisinin and artesunate has been induced in *P. chabaudi chabaudi*, growing the parasites in presence of increasing drug concentrations.

Although clinical resistance to artemisinin has not been yet confirmed, three types of evidence indicate that the risk for artemisinin resistance is emerging:

a) decreasing sensitivity of *P. falciparum* to artemisinin derivatives

In China, where artemisinin derivatives were deployed for more than a decade on a large scale as monotherapy, the *in vitro* sensitivity of *P. falciparum* to artesunate fell significantly between 1988 and 1999, i.e. the 50% inhibitory concentration (IC$_{50}$) tripled and the MIC doubled. In Viet Nam, where artemisinin monotherapy was also deployed on a large scale, the artemisinin IC$_{50}$ remained stable between 1998 and 2001, while the IC$_{90}$ and the IC$_{99}$ doubled and quadrupled, respectively. On the other hand, in countries such as Cambodia, Cameroon or Thailand, where the deployment of artemisinin monotherapy was more contained, there has not been *in vitro* evidence of an increased IC$_{50}$ value for artemisinin derivatives.

b) decreasing drug efficacy from therapeutic efficacy studies

In Viet Nam, the efficacy of artesunate at a dose of 12 mg/kg over 5 days was 71–87.5% but increased to 93.1% at a dose of 16 mg/kg over 7 days. As for initial resistance to all antimalarial medicines, most of the failures were late treatment failures; however, it has been shown that failures after artesunate treatment result not only from decreased sensitivity of strains to artesunate but also from relatively high pretreatment parasitaemia.

c) decreasing drug efficacy from isolated case reports

Four cases, two in India and two in Thailand, are suspected treatment failures. The precise immunological status and the presence or absence of genetic disease were not established in all patients, and drug quality control was not evaluated. In India, an adult still had parasitaemia after 5-day parenteral treatment with artemether (total dose, 480 mg
administered by intramuscular injection), and another adult reported recrudescence on day 14 after 7-day treatment with artesunate at a dose of 13.3 mg/kg. In Thailand, two children aged 2 and 5 years had positive blood smears on day 7 after a dose of 12 mg/kg artesunate, and one had persistent parasitaemia throughout treatment.

Currently, the consumption of artemisinin monotherapies, often of heterogeneous quality, is unacceptably high and is increasing, mainly in the private sector. Artemisinin produces early remission of clinical symptoms of malaria and therefore, adherence to the full 7-day treatment regimen is generally poor. While increased drug pressure is probably the main determinant for spreading drug resistance to antimalarial drugs, high exposure of the parasite to incomplete treatment courses and to medicines of substandard quality may also play a significant role. If the high consumption of oral monotherapies is not reversed in favour of quality ACTs as recommended by WHO, the development and spread of resistance to artemisinin derivatives is very likely to occur, as has been the case with other antimalarial monotherapies.

2. Implications for industry of the WHO Guidelines for treatment of malaria

WHO has recently published Guidelines for the treatment of malaria that provides comprehensive, global and evidence-based recommendations for the formulation of national policies and protocols for treatment of both uncomplicated and severe malaria. In addition, the WHO Guidelines include recommendations for treatment of special groups (young children, pregnant women, people living with HIV/AIDS), travellers (from non-endemic malaria regions) and treatment in epidemics and complex emergency situations.

The standards for drug efficacy have been raised: medicines must be discontinued before resistance reaches 10% treatment failure rates (assessed through monitoring of therapeutic efficacy at 28 days) and new antimalarial medicines must have therapeutic efficacy higher than 95%.

The WHO Guidelines recommend parasitological confirmation (microscopy or RDT) before treatment, with the only exceptions for children under 5 years of age in areas of high transmission, where treatment in this group should be based on clinical diagnosis, and for suspected severe malaria if parasitological confirmation is not immediately possible.

a) uncomplicated P. falciparum malaria

ACTs are recommended for all cases of uncomplicated falciparum malaria except in the first trimester of pregnancy, during which ACTs should be given only if no other effective alternative antimalarial medicine is available. The following ACTs are recommended as first-line treatment of malaria: i) artemether-lumefantrine; ii) artesunate+amodiaquine; iii) artesunate+mefloquine; iv) artesunate+sulfadoxine-pyrimethamine. None of the artemisinin derivatives (oral, rectal, or parenteral formulations) should be used as monotherapy for treatment of uncomplicated malaria. For second-line treatment, the following options are recommended: i) alternative ACT or ii) quinine in combination with either tetracycline or doxycycline or clindamycin.

* http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf,
b) *P. vivax* malaria

The current options are recommended for treatment of vivax malaria: i) chloroquine+ primaquine; ii) amodiaquine+primaquine for treatment of chloroquine-resistant vivax malaria. Where ACT is the first-line treatment of *P. falciparum* malaria, this may also be used for *P. vivax* malaria in combination with primaquine, with the exception of artesunate+sulfadoxine-pyrimethamine, which is not effective against this species.

c) severe *P. falciparum* malaria

Quinine or an artemisinin derivative (artesunate, artemether or artemotil) by i.v. or i.m. route are recommended for treatment of severe malaria. This must be followed by a full treatment course of an effective ACT as soon as patients are able to tolerate oral medication. Artemisinin derivatives administered through the rectal route are recommended only for pre-referral treatment of severe malaria.

The implications for the pharmaceutical industry of the new WHO malaria treatment guidelines are to reorient production and marketing activities to ensure that:

- Artemisinin monotherapies are not used for treatment of uncomplicated malaria, whether in the form of tablets, oral suspensions, suppositories, recto-capsules or vials for parenteral administration.
- Artemisinin monotherapies in rectal formulations are used only for pre-referral treatment of severe malaria.
- Artemisinin monotherapies in parenteral formulations are only used for the management of severe malaria.

3. Antimalarial medicines of the future

The ideal product profile of antimalarial medicines for large-scale deployment in malaria endemic countries includes the following properties:

- Highly effective in providing both clinical and parasitological cure
- Very safe, including in infancy and pregnancy
- Guaranteed against resistance
- Potent anti-gametocyte (transmission blocking) activity
- Effective against all malaria species
- Have applications in intermittent preventive treatment
- Available in fixed-dose combinations
- Simple regimen – ideally as single dose
- Long shelf-life (at least 3 years)
- Available in paediatric formulations and course-of-therapy packaging

The current treatment strategy to delay emergence of resistance to antimalarial medicines is to use two medicines in combination. In the future, it should be possible to combine more than two active pharmaceutical ingredients, as in the case of medicines to treat other diseases, such as TB and leprosy. In addition, the spread of resistant genes could be reduced by including transmission-blocking components of the drugs. Research on molecular mechanisms of resistance would lead to more strategic combinations, in which the partner drugs have unrelated modes of action and different biochemical targets of the parasites.
Safety is a major requirement for antimalarial medicines, since consumption of antimalarial medicines is very high (estimated at around 315 million treatment courses per year in Africa and more than 0.5 billion in the world), over-the-counter use and self-treatment are common and pharmacovigilance systems in malaria-endemic countries are poor. Paradoxically, while safety in pregnancy and infancy is critical, as these are the groups most vulnerable to malaria, all new antimalarials have a restricted labelling for these groups. Therefore, safety of antimalarials in these vulnerable population groups should be addressed as part of the drug development plan.

4. Current status of ACT implementation

In 2000, before WHO delivered its policy recommendations on ACT, only a few countries in South-East Asia (Cambodia, Thailand and Viet Nam) deployed these medicines on a pilot basis in selected provinces/districts. To date, 60 countries, the majority countries with falciparum-resistant malaria, have adopted ACT in their national treatment policy, primarily as first-line treatment. The adoption of these medicines has occurred over a relatively short period of time – most countries adopted these medicines in 2004 and 2005, following GFATM's appeal for increased funding for ACTs. A total of 33 countries are deploying ACTs in general health services to variable extent, and implementation rates are higher in South America (71%) and Asia (65%) compared to Africa (44%), due to both the higher malaria burden and poverty in the latter.

Although more countries have adopted artemether-lumefantrine as first-line treatment (26) compared to artesunate+amodiaquine (16), in 2005 orders by UN procurement agencies for artesunate+amodiaquine exceeded those for artemether-lumefantrine. The selection of a new treatment policy at country level is a complex process, involving review of therapeutic efficacy studies and consensus building among many stakeholders. However, even after completion of this process, country choices of ACTs in 2005 have changed following global product shortage or failure to meet Good Manufacturing Practices by the respective manufacturers.

There is generally a lag time of 12–18 months between country adoption and implementation, due to multiple complex factors often occurring in combination, such as:

- late disbursements by external funding agencies,
- complex financial/procurement requirements of funding agencies,
- administrative/procedural conflicts between national procedures and those of international financial and procurement agencies,
- administrative delays in transferring funds to countries and back to international procurement agencies,
- lack of experience in drug supply management, with antimalarial medicines presenting with limited shelf-life (2 years) and multiple course-of-therapy blister packs,
- poor capacity for estimating drug requirements, poor stock management and drug supply and distribution,
- late re-ordering at peripheral and central levels, and sometimes even conflicting interests between manufacturers of competing ACTs, with attempts to revert treatment policy decisions or to influence international tenders.
WHO will work more closely with recipient Ministries of Health and with the main funding agencies such as the GFATM and the World Bank to resolve the major bottlenecks in financial disbursements and procurement.

5. Forecast of ACTs demand for the public sector

The procurement of ACTs for public sector use by WHO represents approximately 80% of orders placed through the UN Agencies, most of the remaining being procured by UNICEF. In 2005 the orders placed for ACTs through WHO showed a major increase compared to 2004, and the total annual reached 13.9 million treatment courses of artesunate+amodiaquine, 9.9 million treatment courses of artemether-lumefantrine and 5.6 million treatment courses of artesunate+sulfadoxine-pyrimethamine.

The procurement of ACTs for the public sector on a global level was relatively low in 2001 and 2002 (0.5–0.6 million treatment courses) and started to increase in 2003 (2.1 million treatment courses), 2004 (5 million treatment courses) and reached 31.3 million treatment courses ordered and delivered in 2005. The number of treatments delivered in the first part of 2006 have increased compared with the number of treatments delivered in the same period in 2005. From 1 January to 15 April, the number of treatments of artemether-lumefantrine has increased from 1.1 million in 2005 to 17 million in 2006.

Africa, south of the Sahara represents the major market for ACTs, due to its very high malaria burden; 36 African countries have adopted ACTs, 16 of them are deploying these medicines in the public sector, and a total of 25.5 million treatment courses have been procured and delivered in these countries in 2005.

Based on the trends of country adoption and implementations, and availability of international funds for ACT procurement, the global forecast for ACT for public sector use is 110 million treatment courses for 2006. The demand for the public sector is expected to increase to 155 million in 2007 and to 200 million in 2008, while the epidemiological needs for malaria treatments are estimated at more than 500 million treatment courses per year, considering both falciparum and vivax malaria.

The demand and market size for ACTs are in rapid expansion, and needs far exceed the current procurement figures. Among the multiple factors that influence the receptivity of the market and product penetration, the following deserve specific attention:

♦ availability of new fixed-dose combinations,
♦ price,
♦ paediatric formulations,
♦ penetration in the private sector,
♦ international funding initiatives
  (e.g. global ACT subsidy, round 6 of GFATM), and
♦ managerial, procurement, logistic capacity at country level.

6. WHO prequalification of antimalarial medicines

The WHO prequalification programme, a United Nations project managed by WHO, is an action plan for expanding access to HIV/AIDS, tuberculosis and malaria medicines of ensured quality, efficacy and safety, using international funds (for detailed information
The prequalification programme is voluntary for participating manufacturers, open to both innovators and multisource/generic manufacturers, and operates at no cost/fee for applicants (in future, fees are considered). It is based on general procedures and standards approved through WHO Expert Committee system involving all WHO Member States and WHO Governing bodies, and supported by the International Conference of Drug Regulatory Authorities (ICDRA) in 2002 and 2004, representing more than 100 national drug regulatory authorities; procedures will also be discussed in 12th ICDRA 2006.

The expected outcome of the prequalification programme is to generate public lists of products and manufacturing units meeting international norms and standards on quality, safety, and efficacy. It also contributes to capacity building and harmonization among National Drug Regulatory Authorities (DRAs), manufacturers, WHO technical programmes, NGOs and procurement agencies. In addition, it ensures continuous monitoring of prequalified products, based on prequalified quality control laboratories.

WHO is managing the prequalification programme on behalf of the United Nations. It provides technical and scientific support, and guarantees that international norms and standards are applied throughout the whole process, including product dossier assessment, inspection (GMP, GCP, GLP) and quality control. The partners include UNICEF, UNFPA, UNAIDS and the World Bank. The WHO technical programmes (Global Malaria Programme, Stop TB and HIV/AIDS Departments) define the list of products to be prequalified.

The assessment is carried out by qualified assessors and inspectors from National DRAs (also from National Quality Control Laboratories) of ICH and associated countries, and inspectorates belonging to Pharmaceutical Inspection Cooperation Scheme countries (PIC/S). The assessment of products’ dossiers on quality specifications, pharmaceutical development, bioequivalence, etc. is done by teams of professionals from national drug regulatory authorities, which includes at present Brazil, China, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Indonesia, Malaysia, Philippines, Spain, South Africa, Sweden, Switzerland, Uganda, UK, UR Tanzania and Zimbabwe. The assessment is carried out by 8 to 16 assessors together during one week at least every two months at UNICEF in Copenhagen. Every dossier is assessed by at least two assessors, producing an assessment report. A letter is then sent to the applicant summarizing the findings and asking for clarification and additional data if necessary.

The assessment of product dossier has a specific procedure for innovator products: if approved by stringent authorities like EMEA and US FDA the procedure is abridged, trusting the expertise of well-established DRAs. The assessment in these cases is based on the report from the DRAs, WHO Certificate of Pharmaceutical Product (CPP), batch
certificate and update on changes. For multi-source products, the full dossier is requested with all data and information on quality (information on starting materials and finished product including API details, specifications, stability data, formulation, manufacturing method, packaging, labelling, etc.) and efficacy and safety (bioequivalence study or clinical study report). A confidentiality agreement has been signed between US FDA and WHO for mutual recognition of scientific assessment based on information exchange; the same approach will soon apply for EU Art. 58 and Canadian JCPA procedure. A commercial sample is requested, but not always analysed before prequalification (quality control analysis is increasingly part of proactive follow up after the product has been prequalified).

Prequalification requirements for generics are fully in line with major regulatory agencies. For instance, the US FDA requirements for generic drugs (www.fda.gov/cder/ogd) state that generic drugs must: i) contain the same active ingredients as the innovator drug; ii) be identical in strength, dosage form, and route of administration; iii) have the same use indications; iv) meet the same batch requirements for identity, strength, purity and quality; v) be manufactured under the same strict standards of GMP required for innovator products; vi) be bioequivalent. In practice for many products in the prequalification pipeline no innovator “reference” product may be available and, for this reason, they cannot be defined as generics. If the medicines are not generics, then the full data set needs to be submitted to prove safety (including preclinical toxicology) as well as efficacy.

The inspection procedure involves a WHO representative (qualified GMP inspector) and an inspector from well-established inspectorate (Pharmaceutical Inspection Cooperation Scheme countries – PIC/S). National inspector(s) is(are) invited to be part of the team but have no decision making power, because of possible different GMP standards and potential conflict of interest.

The inspection covers the following areas:

♦ manufacturing site (final product, packaging),
♦ active pharmaceutical ingredient (API),
♦ research laboratory or Contract Research Organization (CRO).

As part of the prequalification programme a series of training activities are being conducted. In 2005, three one-week comprehensive training courses on quality of TB drugs and ARVs were carried out in China, Malaysia, Ukraine. GMP training courses have been conducted in South Africa and China, and a new GMP training course will be conducted in United Republic of Tanzania. In addition, training has been organized for QC lab officials. Specific training courses for regulators and industries on antimalarial medicines have been conducted in Thailand (2004) and China (2006). An introduction course to the prequalification programme has been conducted in Viet Nam (2006), and two courses are planned on antimalarials and anti-TB medicines, in United Republic of Tanzania and China, respectively. All training course materials are posted on the web site to assist manufacturers to prepare quality dossiers and to be ready for inspections.

The current situation of prequalified products for the three diseases, with dossiers in the pipeline, is presented below:

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Quantity</th>
<th>Pipeline (2006)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV related medicines</td>
<td>121</td>
<td>200</td>
</tr>
<tr>
<td>Anti-tuberculosis medicines</td>
<td>8</td>
<td>65</td>
</tr>
<tr>
<td>Antimalarial medicines</td>
<td>5</td>
<td>40</td>
</tr>
<tr>
<td>Total</td>
<td>134</td>
<td>305</td>
</tr>
</tbody>
</table>

The antimalarials prequalified so far include:

- Artesunate 50 mg tabs - Sanofi-Synthelabo – box of 25 blisters of 12
- Artemether 20 mg tabs - Novartis Pharma – box of 30 blisters of 6, 12, 18 or 24
- Lumefantrine 120 mg
- Artemotil 50 mg/ml, sol. inj. - ARTECEF BV – 10 or 100 ampoules, each of 1 ml
- Artemotil 150 mg/ml, sol. inj. - ARTECEF BV – 10 or 100 ampoules, each of 1 ml
- Artesunate 50 mg tabs - Guilin Pharmaceutical Co Ltd PVC/AI – blisters of 12

The prequalification of artemisinin derivatives have encountered problems because very few are innovator products and most are not typical generics. Very few artemisinin derivatives are recommended by treatment guidelines approved in ICH and associated countries, and in general there are few DRAs and regulatory experts that have experience with these compounds. In addition the artemisinin derivatives often present quality related issues: manufacturers do not comply with GMP (even if located in the EU or EFTA countries – products not registered in the country of origin and produced for export only). Many dossiers have outstanding deficiencies in proving the quality of the product: e.g. non-compliance with established specifications or poorly defined manufacturers specifications; stability data either missing or not meeting requirements; no method validation, etc. Most manufacturers can overcome these problems if motivated, but this may take a lot of time.

For most of the artemisinin derivatives there is a lack of reference products for bio-equivalence studies. For generic drugs, safety and efficacy are proved by bio-equivalence studies assuming that the same blood concentrations of active ingredient give the same safety and efficacy profile. The only reference products are artesunate from Guilin Pharma and the artemether+lumefantrine FDC from Novartis. In relation to safety and efficacy, product dossier often have insufficient reports of the evidence about the clinical efficacy and safety, no fully documented trial reports, no full evaluation of published literature, and often no characterization of pharmacokinetic properties of the product. Often the product dossier contains incorrect general statements, such as “No interaction known”, clearly not true; “No (or minimal) adverse events”, available from literature survey. In addition the galenical development history is often not provided, making difficult to assess if results of earlier studies apply to current formulation. Many manufacturers applying for prequalification of artemisinin derivatives have very limited experience in these areas.

A series of measures have been taken to get more products prequalified, despite the limited resources. The prequalification programme started with only one professional; today it has three and by the end of 2006 it will have at least six. Internal SOPs and work
procedures to facilitate process have been created, specific “Note for Applicants” on antimalarials have been prepared and literature reviews for the various artemisinin derivatives will be made available to manufacturers. More direct discussions with manufacturers have started, including specific training workshops for manufacturers producing antimalarials.

In conclusion, a relatively large number of products and suppliers comply with the standards (mostly ARVs so far) and many potential suppliers appreciate feedback and are willing to improve. Unfortunately only a limited number of products have met the required standards (especially malaria products), and specific requirements (data to be generated, tests to be carried out, GMP upgrade, etc.) will demand time and funds. More technical support to manufacturers is needed especially to companies in developing countries.

7. WHO/UNICEF procurement of ACTs

In March 2003, two countries (Burundi and Zanzibar) adopted as first-line treatment artesunate+amodiaquine, for which there was no prequalified product available nor likely to be prequalified in the short term. At that time UNICEF and WHO established an interim procedure for issuing joint request for proposals for ACTs which lacked prequalified products.

A series of joint tenders were issued from 2003 to 2005, with evaluation based on a product quality questionnaire (which has now become the Interagency quality questionnaire), review of compliance to WHO-Good Manufacturing, registration information (countries), Active Pharmaceutical Ingredient, stability, resulting shelf-life and storage conditions. Quality assurance is based on a review of the documentation submitted, effected jointly by UNICEF Pharmaceutical Team and WHO (Procurement team with assistance from QSM when necessary).

The list of products selected considered as acceptable, based on the quality evaluation, is submitted to the WHO Contract Review Committee (CRC). The contract is awarded by the CRC to the bidder offering the lowest acceptable prices, shortest lead time, most suitable product conditioning in compliance with all instructions, contractual and technical provisions/ terms contained in the Request for Proposal. Once accepted, a letter of agreement is sent to the manufacturer, setting the price and other conditions for a period (usually 1 year). The product is then added to the Malaria catalogue of the electronic catalogue of WHO (WebBuy).

Following the first WHO/UNICEF joint tender in March 2003, no co-packaged product of artesunate+amodiaquine could be selected, due to lack of stability data. By June, only two products (artesunate and amodiaquine in separate blisters) satisfied the evaluation and allowed to place the first orders at a high cost (US$ 2.60 per adult treatment course). By December of the same year, it was possible to select three artesunate 50 mg tabs and two for amodiaquine 153 mg base tabs, lowering the price of artesunate+amodiaquine adult treatment to US$ 1.68.

At the second WHO/UNICEF joint tender, in 2004, a series of ACTs (in co-blisters) were initially selected: five offers of artesunate+amodiaquine, one offer of
artesunate+mefloquine, one offer of artesunate+sulfadoxine-pyrimethamine and one offer of amodiaquine+ sulfadoxine-pyrimethamine. However, after the GMP inspection of the manufacturing site, only three offers of artesunate+amodiaquine were accepted for procurement.

To the third WHO/UNICEF joint tender, in 2005, manufacturers responded with better quality products and several artemisinin derivatives GMP compliant were selected. This includes artesunate+amodiaquine from CIPLA, IPCA and Sanofi/Aventis, artesunate+ mefloquine from MEPHA, artesunate+sulfadoxine-pyrimethamine from Guilin, artesunate suppositories from MEPHA and artesunate i.v./i.m. from Guilin. These products are being procured by UN procurement agencies and international drug suppliers. They are all included in the WHO e-procurement (WHO WebBuy) catalogue, which is in use across the Organization to allow standardization of items, rapid procurement and assistance in programme planning.
ANNEX II

List of participating companies

**Activa Pharmaceuticals (FCZ)**
Z-2-19, SAIF Zone
P.B. No. 9608
Sharjah
UNITED ARAB EMIRATES
Representative:
Mr Pradeep NAMBIAR, Managing Director

**Ajanta Pharma Limited**
Ajanta House
Government Industrial Area
Charkop, Kanivli (W)
Mumbai 400 067
INDIA
Representative:
Mr Mani KURIAKOSE, Senior General Manager, Europe

**Arenco Pharmaceutica**
Arenco Pharmaceutica
Lammerdries 15
Geel, BE 2440
BELGIUM
Representatives:
Mr Marc MOMMAERTS, Chief Executive Officer
Professor Jacqueline PLAIZIER-VERCAMMEN,
Bernard TEISSEIRE, Sales Manager, West Africa

**Chongqing Holley Holding Co., Ltd.**
Chongqing Holley Holding
F12 Guangyu Building No. 76
North Jianxin Road
Jiangbei District
Chongqing 400020
CHINA
Representatives:
Dr Nelson TAN, Vice President
Dr Wei LI, Technical Director

**Cipla Limited**
Mumbai Central
Mumbai 400 008
INDIA
Representatives:
Dr William HADDAD, CEO, Biogenerics, Inc.
Dafra Pharma NV
Slachthuisstraat 30/7
B 2300 Turnhout
BELGIUM
Representatives:
Mr Bruno JANSEN, Chief Executive Officer
Dr Herwig JANSEN, Director, Research and Development
Mr Paul LONGMOOR, Regional Director
Mr Edwin MINCKE, Export Manager

Danpong-Adams Pharmaceutical Industry (Ghana) Ltd.
67 Nungua Link
Spintex Road
Baatsona, Accra
GHANA
Representatives:
Mr Yaw Adu-Agyei GYAMFI, Chief Executive Officer
Mr Kwasi Poku BOATENG, Director, Quality Assurance

Denk Pharma GmbH & Co. KG
Prinzregentenstrasse 79
81675 München
GERMANY
Representative:
Mr Frank ZIMMERMANN, International Sales Manager

Guilin Pharmaceutical Co., Ltd.
17 Shanghai Road
Guilin (Guangxi)
CHINA
Representatives:
Mr Xiaohua YAN, Chairman of the Board and General Manager
Mr Xiaojie FENG, International Cooperation Majordomo & Representative of Guilin Pharma in Europe
Ms Bin JIANG, Director of Overseas Department
Ms Yahui WU, Drug International Registration Group Overseas Department

Holley-Cotec Pharmaceuticals
Beijing Holley Cotec Pharmaceutical Co.
Holleypharm, 4300 Jiangnan road,
Hangzhou
CHINA
Representatives:
Mr Chun Ming LU, President
Mr Ze Xun MU, Sales Director
Mr David JIANG, Marketing Manager
Holleypharm France
34 avenue Franklin Roosevelt
Bat A
77210 Avon
FRANCE
   Representative:
   Dr Claude FAURANT, Managing Director of Holleypharm France and Senior Vice-
   President of Holley-Cotec

Hovid Bhd
121 Jalan Tunku Abdul Rahman
30010 Ipoh, Perak
MALAYSIA
   Representative:
   Mr David HO Sue San, Managing Director

IPCA Laboratories Ltd.
International House, 48 Kandivli Industrial Estate
Kandivli (West), Mumbai 400067
INDIA
   Representatives:
   Mr Yatish Kumar BANSAL, Vice President - R&D Formulation

Kakwa Biofarm, Ltd.
P.O. Box 5001
Bamenda
REPUBLIC OF CAMEROON
   Representatives:
   Dr Nghe TOYANG, Chief Executive Officer
   Ms Sylveria TOYANG, Executive Assistant
   Professor Achille BENAKIS, ACT Consultant

Kinapharma Ltd.
B920/10, Mausoleum Lane
Dadeban Road
North Industrial Area, North Kaneshie
Accra
GHANA
   Representative:
   Mr Kofi Nsiah-POKU

Kunming Pharmaceuticals
166 Keyi Road, State New & High Development Zone
Kunming 650 106, Yunnan Province,
CHINA
   Representatives:
   Mr Yang Shang HUA, Product Manager, Artemether Products
Mediplantex National Pharmaceutical Joint Stock Co.
358 Giaphong Road
Thanh Xuan District
Hanoi
VIET NAM
Representative:
Mr Nguyen Cong BINH, Deputy Manager

Mepha Ltd.
Dornacherstrasse 114
CH 4147 Aesch
SWITZERLAND
Representative:
Mr Dieter MEPPIEL, International Product Manager, Malaria

Phyto-Riker Pharmaceuticals Ltd.
Mile 7, off Nsawam Road
P.O.Box AN5266, Dome
Accra North
GHANA
Representative:
Mr Jervis DANQUAH

Sanofi-Aventis
174, avenue de France
75635 Paris
Cedex 13
FRANCE
Representatives:
Dr Robert SEBBAG, Vice President, Director, Access to Medicines
Dr François BOMPART, Vice President, Director, Impact Malaria
Dr Alain AUMONIER, Vice President, Relations with International Institutions

Saokim Pharma
Quang Minh Industrial Park
Me Linh District - Vinh Phuc Province
VIET NAM
Representative:
Mr DUONG Ngoc Van, Vice General Director

Scanpharm A/S
Topstykket 12
DK-3460 Birkeroed
DENMARK
Representative:
Dr Olé Bjorn JENSEN, Managing Director
Shelys Pharmaceuticals Ltd.
New Bagamoyo Rd.
Mwenge
PO Box 3016
Dar-es-Salaam
UR TANZANIA
Representative:
Mr Rahul MALHOTRA, Managing Director

Standard Pharma Ltd.
21B West Tower China Travel Comm'l Bldg.
Qiao Lin Street, Tianhe Bei Road
CHINA
Representatives:
Dr Song Ming YANG, Chairman
Ms Christine LIN, Managing Director
Mr Kelvin ZHOU, Technician and Production Director

Themis Medicare Ltd
11/12 Udyog Nagar, S.V. Road,
Goregaon (W), Mumbai 400 104
INDIA
Representatives:
Dr Dinesh PATEL, Managing Director & CEO

OBSERVERS

Medicines for Malaria Venture (MMV)
20, route de Pré-Bois
1215 Geneva 15
Switzerland
Representatives:
Dr P. V. VENUGOPAL, Director, International Operations
Ms Renia COGHLAN, Global Access Programme Officer
WORLD HEALTH ORGANIZATION SECRETARIAT

Global Malaria Programme (GMP)

Dr Arata KOCHI, Director
Dr Andrea BOSMAN, Medical Officer (Secretary)
Dr Kamini Nirmala MENDIS, Coordinator
Dr Peter Ehizibue OLUIMESE, Medical Officer
Dr Pascal RINGWALD, Medical Officer

Roll Back Malaria Partnership Secretariat (RPS)

Dr Maryse DUGUE, Manager

Quality Assurance and Safety: Medicines (QSM)

Dr Lembit RAGO, Coordinator

Contracting and Procurement Services (CPS)

Mrs Françoise Blanche MAS, Procurement Officer (unable to attend)